Patexia. Community

Our Members

All »
Apr 13, 2012
Medtronic initiates US drug-eluting Balloon study for peripheral artery disease
Share this article

Medtronic, Inc. announced today the start of the IN.PACT SFA II study, the company’s first US clinical trial for its IN.PACT drug-eluting balloons. The first patients in this landmark study were treated this week. The study will evaluate the safety and effectiveness of the IN.PACT Admiral drug-eluting balloon in the treatment of peripheral artery disease in the superficial femoral artery and/or proximal popliteal artery. The study will involve several hundred patients at up to 55 US sites. Patients will be randomized to treatment with either the IN.PACT Admiral drug-eluting balloon or a traditional non-coated angioplasty balloon. “Drug-eluting balloons represent an exciting and innovative therapy in the advancement of peripheral artery disease treatment,” said  Dr. John Laird, a principal investigator of the study. “The concept of delivering an anti-restenotic agent to the vessel while leaving nothing behind is very attractive.”

Relevant Locations: Minneapolis, MN, USA
Comment (0) Favorite (0)
Be the first to comment.